News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Antonio Passaro: Overall Survival in EGFR-Mutant Advanced NSCLC Treated with First-Line Osimertinib
Antonio Passaro/LinkedIn
Jun 11, 2025, 06:20

Antonio Passaro: Overall Survival in EGFR-Mutant Advanced NSCLC Treated with First-Line Osimertinib

Antonio Passaro, Medical Oncologist and a Medical Director with High Specialization Assignment at the European Institute of Oncology, posted on LinkedIn:

“Real-world outcomes in EGFRm NSCLC: progress has been mad, but not enough!
I have the pleasure to share our latest work recently published in JTO and based on one of the largest real-world datasets to date. We examined the survival outcomes of over 1300 patients with advanced EGFR-mutated NSCLC treated with first-line osimertinib.
While median real-world overall survival reached 28.6 months, the data highlight a sobering reality: patients with brain metastases, liver metastases, TP53 co-mutations, or poor performance status face significantly worse outcomes, and 95% of patients had at least one of these high-risk factors.
Only 58% survived to 2 years, and just 18% to 5 years. Alarmingly, 1 in 3 never received a second line of therapy. These findings underscore a critical point: despite therapeutic advances in the last decade, long-term survival remains limited for most patients.
We must do more, through smarter trial design, molecularly driven strategies, and real-world-informed care models, to meet the complexity and heterogeneity of this disease head-on.”

Title: Overall Survival in EGFR-Mutant Advanced NSCLC Treated With First-Line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States

Authors: Joshua K. Sabari, Helena A. Yu, Parthiv J. Mahadevia, Yanfang Liu, Levon Demirdjian, Yen Hua Chen, Xiayi Wang, Antonio Passaro

Read The Full Article at Journal of Thoracic Oncology.

Antonio Passaro: Overall Survival in EGFR-Mutant Advanced NSCLC Treated with First-Line Osimertinib

More posts featuring Antonio Passaro on OncoDaily.

Antonio Passaro cancer Helena A. Yu Joshua K. Sabari Levon Demirdjian Lung cancer NSCLC OncoDaily Oncology Parthiv J. Mahadevia Xiayi Wang Yanfang Liu Yen Hua Chen
Special Coverage
Blog
Jun 11, 2025, 06:20
Antonio Passaro: Overall Survival in EGFR-Mutant Advanced NSCLC Treated with First-Line Osimertinib
Blog
Jun 11, 2025, 06:11
Yeva Margaryan: The Economist Impact’s 10th Annual World Cancer Series Europe has Officially Begun!
Blog
Jun 11, 2025, 06:06
Yan Leyfman: Honored to be Named One of the 2025 Trailblazers in Higher Education by City and State New York
Blog
Jun 11, 2025, 05:56
Alisher Kahharov: Just Attended the MIB Meeting in Paris
Opinion
Jun 11, 2025, 05:35
Naveen Pemmaraju: Wonderful to honor our amazing fellows
Insight
Jun 11, 2025, 05:24
Common Sense Oncology Webinar: Best of ASCO 2025
Insight
Jun 11, 2025, 05:15
Melanoma Advances at Sylvester Comprehensive Cancer Center: New Trials, Therapies, and Diagnostics
Blog
Jun 11, 2025, 04:57
Olubukola Ayodele: Spotlight on Breast Cancer - Cancer Conversations in the Black Community
Blog
Jun 11, 2025, 04:28
Dr. Doug Flora, a cancer survivor, shares his inspiring journey during Cancer Survivor Month - St. Elizabeth Healthcare
Blog
Jun 11, 2025, 04:05
Natalie Johnson: Fostering Gratitude and Connection at Kidney Cancer Association Retreat
Blog
Jun 11, 2025, 02:08
TRANSiTION Coordinator Addressed a Keynote Speech on TRANSiTION Results at the SUSA Project
Insight
Jun 11, 2025, 01:57
Goutham Sunny Shared a Must Read Article for Residents on Perioperative Management in Urothelial Carcinoma